Wolfspeedの空売り状況は、投資家がWolfspeedの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Wolfspeed (NYSE:WOLF) 株価情報, 空売り情報

Wolfspeed

Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.

Wolfspeed Inc

WOLF ENERGY SERVICES INC by Wolf Energy Services Inc.

Wolf Energy Services Inc

Wolfden Resources Corp

<p>Rosenblatt  analyst Catharine Trebnick   upgrades Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Neutral to Buy and raises the price target from $190 to $235.</p>


News

Upgrades

Price Target

Analyst Ratings

Rosenblatt Upgrades Zscaler to Buy, Raises Price Target to $235

TRNR

Interactive Strength Signs Letter Of Intent And Exclusivity Agreement To Acquire A Connected-Fitness Equipment Business That Earned Over $15M In Revenue In 2024; Acquired Through All-Stock Consideration, Says It Expects To Improve The Target's Profitability Through Potential Operating Synergies

<p><strong>Reaffirms Full Year 2025 Outlook</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Global systemwide sales growth</td>
<td colspan="1" rowspan="1">2 to 3 percent</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. earnings per share</td>
<td colspan="1" rowspan="1">$0.98 to $1.02</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA</td>
<td colspan="1" rowspan="1">$550 to $560 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$100 to $110 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free cash flow</td>
<td colspan="1" rowspan="1">$275 to $285 million</td>
</tr>
</tbody>
</table>
<p></p></figure></p>


Guidance

Wendy's Reaffirms 2025 Outlook, Global Systemwide Sales Growth Of 2% - 3%,
Adj EPS Of $0.98 - $1.02 (Est $1.02)

Earnings

Earnings Beats

Earnings Misses

GWRS

Reported Earlier, Global Water Resources FY 2024 Adj. EPS $0.26 Misses $0.28 Estimate, Sales $52.692M Beat $52.400M Estimate

<p>Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.64 by 18.75 percent. This is a 40.74 percent increase over earnings of $0.54 per share from the same period last year.  The company reported quarterly sales of $415.60 million which beat the analyst consensus estimate of $378.44 million by 9.82 percent.  This is a 27.64 percent increase over sales of $325.60 million the same period last year.</p>


Marex Group Q4 Adj EPS $0.76 Beats $0.64 Estimate, Revenue $415.60M Beat $378.44M Estimate

<p>Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.30) by 36.67 percent. This is a 30.51 percent increase over losses of $(0.59) per share from the same period last year.</p>


MNMD

Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Sees 2025 Revenue Of $125M-$142M (Vs. Cons. Of $133.648M), Adjusted EBITDA Of $14M-$22M

WIIM

Macy's shares are trading lower following weak FY25 guidance.

Wendy's Reveals Long-term Financial Algorithm Of 3-4% Annual Net Unit Growth, 5-6% Annual Systemwide Sales Growth, And 7-8% Annual Adjusted EBITDA Growth

<p>Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.  The company reported quarterly sales of $350.63 million which beat the analyst consensus estimate of $300.11 million by 16.83 percent.  This is a 93.35 percent increase over sales of $181.34 million the same period last year.</p>


REAX

Real Brokerage Q4 GAAP EPS $(0.03) Beats $(0.04) Estimate, Sales $350.63M Beat $300.11M Estimate

<p>Needham  analyst Quinn Bolton   reiterates Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with a Buy and maintains $17 price target.</p>


Reiteration

RGTI

Needham Reiterates Buy on Rigetti Computing, Maintains $17 Price Target

Wendy's To Host Its 2025 Investor Day Today; Outlines Expectations To Add 1,000 Net New Restaurants Globally By 2028

<p>Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year.  The company reported quarterly sales of $60.10 million which beat the analyst consensus estimate of $58.10 million by 3.43 percent.  This is a 35.39 percent increase over sales of $44.39 million the same period last year.</p>


XERS

Xeris Biopharma Holdings Q4 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $60.10M Beat $58.10M Estimate

<p>BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.31) by 225.81 percent. This is a 320.83 percent decrease over losses of $(0.24) per share from the same period last year.  The company reported quarterly sales of $30.37 million which missed the analyst consensus estimate of $34.22 million by 11.26 percent.  This is a 14.47 percent decrease over sales of $35.51 million the same period last year.</p>


BlackSky Technology Q4 2024 GAAP EPS $(1.01) Misses $(0.31) Estimate, Sales $30.37M Miss $34.22M Estimate

General

SATS

Delta Air Lines  To Use Hughes Fusion Simultaneous Multi-Orbit In-Flight Connectivity SolutionFor Select New Delivery A350 And A321neo Aircraft

KVHI

KVH Industries Q4 2024 GAAP EPS $(0.22) Misses $(0.04) Estimate, Sales $26.917M Miss $28.010M Estimate

<p>In the preceding three months, 6 analysts have released ratings for American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.83, a high estimate of $20.00, and a low estimate of $16.00. Observing a downward trend, the current average is 7.76% lower than the prior average price target of $19.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741262447_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of American Eagle Outfitters by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to American Eagle Outfitters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Eagle Outfitters compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of American Eagle Outfitters's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into American Eagle Outfitters's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AEO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on American Eagle Outfitters analyst ratings.</strong></a></p>
<h2>About American Eagle Outfitters</h2>
<p>American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the vast majority of its revenue from the United States.</p>
<h3>Breaking Down American Eagle Outfitters's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining American Eagle Outfitters's financials over 3 months reveals challenges. As of 31 October, 2024, the company experienced a decline of approximately <strong>-0.92%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> American Eagle Outfitters's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.21%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> American Eagle Outfitters's ROE excels beyond industry benchmarks, reaching <strong>4.65%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> American Eagle Outfitters's ROA excels beyond industry benchmarks, reaching <strong>2.2%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.8</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying American Eagle Outfitters: Insights From 6 Analyst Reviews

<p>Throughout the last three months, 5 analysts have evaluated Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.0, a high estimate of $8.00, and a low estimate of $6.00. Witnessing a positive shift, the current average has risen by 2.94% from the previous average price target of $6.80.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741262432_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Ocugen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ocugen. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocugen compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Ocugen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Ocugen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OCGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ocugen analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Ocugen: A Closer Look</h2>
<p>Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").</p>
<h3>Financial Milestones: Ocugen's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Ocugen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-69.29%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ocugen's net margin excels beyond industry benchmarks, reaching <strong>-1141.73%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Ocugen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-45.07%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ocugen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-25.31%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Ocugen's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OCGN

Beyond The Numbers: 5 Analysts Discuss Ocugen Stock

<p>Ratings for TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.5, along with a high estimate of $15.00 and a low estimate of $9.00. A decline of 3.85% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741262422_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of TScan Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TScan Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TScan Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of TScan Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of TScan Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TCRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on TScan Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know TScan Therapeutics Better</h2>
<p>TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.</p>
<h3>TScan Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> TScan Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-73.01%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> TScan Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-2849.09%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TScan Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-12.34%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> TScan Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-8.27%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> TScan Therapeutics's debt-to-equity ratio surpasses industry norms, standing at <strong>0.39</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TCRX

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views

<p>This three-year agreement will allow EYSA to integrate Palantir's software with the goal of accelerating the development of mobility applications and use cases across its various operational lines, as well as capturing new business opportunities.</p>


PLTR

EYSA Jointly Announces Strategic Partnership With Palantir Technologies

Legal

Press Releases

WOLF Investors Have Opportunity to Lead Wolfspeed, Inc. Securities Fraud Lawsuit with the Schall Law Firm

WOLF DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Wolfspeed, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 17 Deadline in Securities Class Action – WOLF

Small Cap

WOLF Final Deadline for Wolfspeed, Inc. Securities Fraud Lawsuit Today

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Wolfspeed Lawsuit - WOLF

Faruqi & Faruqi Reminds Wolfspeed Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – WOLF

WOLF Deadline: WOLF Investors Have Opportunity to Lead Wolfspeed, Inc. Securities Fraud Lawsuit

DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Wolfspeed Launches New Gen 4 MOSFET Technology Platform to Deliver Breakthrough Performance in Real-World Conditions for High-Power Applications

Wolfspeed Reports Financial Results for the Second Quarter of Fiscal Year 2025

HUMA

WOLF

ZETA

Ambarella

Alpha and Omega Semiconductor Limited - Common Shares

Alpha & Omega

Blaize Holdings

CEVA

Canadian Solar

Diodes

Himax Technologies, Inc. - American depositary shares, each of which represents two ordinary shares.

Himax Techs

Intchains Group Limited - American Depositary Shares

Intchains Gr

ChipMOS TECHNOLOGIES INC. - American Depositary Shares

ChipMOS TECHNOLOGIES

indie Semiconductor, Inc. - Class A Common Stock

Indie Semiconductor

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

JinkoSolar Holding Co

Kopin

SEALSQ

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

MaxLinear

Navitas Semiconductor Corporation - Common Stock

Navitas Semiconductor

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions

Impinj

Rigetti Computing

Silicon Motion Technology Corporation - American Depositary Shares, each representing four ordinary shares

Silicon Motion Technology

SkyWater Technology

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Wolfspeed

空売り

Wolfspeed (NYSE:WOLF) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル